S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:LTRN

Lantern Pharma (LTRN) Stock Price, News & Analysis

$8.80
-0.98 (-10.02%)
(As of 03/28/2024 ET)
Today's Range
$8.50
$10.06
50-Day Range
$3.87
$10.65
52-Week Range
$2.38
$11.99
Volume
307,861 shs
Average Volume
263,818 shs
Market Capitalization
$94.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Lantern Pharma MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of Lantern Pharma in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$607,674 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.02) to ($1.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.40 out of 5 stars

Medical Sector

898th out of 938 stocks

Pharmaceutical Preparations Industry

404th out of 423 stocks

LTRN stock logo

About Lantern Pharma Stock (NASDAQ:LTRN)

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

LTRN Stock Price History

LTRN Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
LTRN: 2023 Results
H.C. Wainwright Reaffirms Their Hold Rating on Lantern Pharma (LTRN)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Recap: Lantern Pharma Q4 Earnings
LTRN May 2024 5.000 call
LTRN Apr 2024 12.500 call
Lantern Pharma Earnings Preview
LTRN Mar 2024 10.000 call
LTRN Oct 2024 5.000 put
LTRN Apr 2024 2.500 call
LTRN Mar 2024 7.500 call
See More Headlines
Receive LTRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2023
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LTRN
Fax
N/A
Employees
22
Year Founded
2013

Profitability

Net Income
$-15,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.76 per share

Miscellaneous

Free Float
9,998,000
Market Cap
$94.51 million
Optionable
Optionable
Beta
1.28

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Panna Sharma PH.D. (Age 53)
    President, CEO & Director
    Comp: $633.25k
  • Mr. David R. Margrave (Age 63)
    CFO & Secretary
    Comp: $394.36k
  • Dr. Kishor Gopaldas Bhatia Ph.D. (Age 69)
    Chief Scientific Officer & Scientific Consultant
    Comp: $184.33k
  • Nicole Leber
    Investor Relations Associate, Finance & Administrative Coordinator
  • Dr. Peter L. Nara D.V.M.
    M.S., Ph.D., Co-Founder & Advisor
  • Mr. Ernest Kitt B.S.
    M.S, Head of Clinical Operations

LTRN Stock Analysis - Frequently Asked Questions

Should I buy or sell Lantern Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LTRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LTRN, but not buy additional shares or sell existing shares.
View LTRN analyst ratings
or view top-rated stocks.

How have LTRN shares performed in 2024?

Lantern Pharma's stock was trading at $4.28 at the start of the year. Since then, LTRN stock has increased by 105.6% and is now trading at $8.80.
View the best growth stocks for 2024 here
.

Are investors shorting Lantern Pharma?

Lantern Pharma saw a increase in short interest in March. As of March 15th, there was short interest totaling 144,600 shares, an increase of 112.6% from the February 29th total of 68,000 shares. Based on an average daily volume of 243,300 shares, the short-interest ratio is presently 0.6 days. Currently, 1.8% of the company's shares are sold short.
View Lantern Pharma's Short Interest
.

When is Lantern Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our LTRN earnings forecast
.

How were Lantern Pharma's earnings last quarter?

Lantern Pharma Inc. (NASDAQ:LTRN) issued its quarterly earnings results on Monday, March, 20th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.18. During the same quarter in the prior year, the company posted ($0.31) earnings per share.

What ETFs hold Lantern Pharma's stock?

ETFs with the largest weight of Lantern Pharma (NASDAQ:LTRN) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX),

What other stocks do shareholders of Lantern Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantern Pharma investors own include Applied Materials (AMAT), ARK Next Generation Internation ETF (ARKW), Conagra Brands (CAG), FedEx (FDX), Lowe's Companies (LOW), PayPal (PYPL), Block (SQ), Vanguard Real Estate ETF (VNQ) and ARK Innovation ETF (ARKK).

When did Lantern Pharma IPO?

Lantern Pharma (LTRN) raised $26 million in an initial public offering (IPO) on Thursday, June 11th 2020. The company issued 1,600,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.

Who are Lantern Pharma's major shareholders?

Lantern Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.43%), Redmond Asset Management LLC (0.37%), Pathway Financial Advisors LLC (0.26%), Meridian Wealth Management LLC (0.18%), Sigma Planning Corp (0.11%) and Dimensional Fund Advisors LP (0.11%). Insiders that own company stock include Aaron GL Fletcher and Leslie W Kreis.
View institutional ownership trends
.

How do I buy shares of Lantern Pharma?

Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LTRN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners